Quick Answer
Zivo Bioscience, Inc. reported Total Revenue of $157.2 thousand for fiscal year 2024.
Zivo Bioscience, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $157.2K +468.6% |
$27.6K | $0.00 | $0.00 -100.0% |
$20.0K | $0.00 |
| Revenue (ASC 606) | $157.2K +468.6% |
$27.6K | $0.00 | — | — | — |
| Net Income | -$13.38M -72.1% |
-$7.78M +11.1% |
-$8.75M +0.1% |
-$8.76M +3.8% |
-$9.11M +20.9% |
-$11.51M +21.4% |
| Diluted EPS | -$4.23 +8.0% |
-$4.60 | — | — | — | — |
| Total Assets | $1.64M +195.7% |
$555.7K -73.8% |
$2.12M -76.4% |
$8.99M +3983.1% |
$220.2K -40.4% |
$369.4K -10.2% |
| Cash and Equivalents | — | — | $1.80M -79.8% |
$8.90M +6357.1% |
$137.9K -60.2% |
$346.1K -11.0% |
| Stockholders Equity | -$514.9K +76.7% |
-$2.21M -20666.7% |
-$10.6K -100.2% |
$6.04M +153.4% |
-$11.31M -35.6% |
-$8.34M +62.6% |
| R&D Expense | $3.13M +127.7% |
$1.38M -38.5% |
$2.24M +14.9% |
$1.95M -48.1% |
$3.75M +62.8% |
$2.31M -18.0% |
| Operating Income | -$13.36M -84.0% |
-$7.26M +16.8% |
-$8.73M -1.0% |
-$8.65M -1.0% |
-$8.56M -2.4% |
-$8.35M -36.2% |
| Gross Profit | $49.0K +321.6% |
$11.6K | $0.00 | — | — | — |
| Shares Outstanding | 3.62M +52.0% |
2.38M +51.7% |
1.57M -83.3% |
9.42M +82.4% |
5.16M -98.8% |
413.04M +129.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $65.6K | +108.3% | +22.9% |
| Revenue (ASC 606) | September 30, 2025 | $65.6K | +108.3% | +22.9% |
| Net Income | September 30, 2025 | -$1.03M | +54.5% | +37.0% |
| Diluted EPS | September 30, 2025 | -$0.27 | +59.7% | +37.2% |
| Total Assets | September 30, 2025 | $559.5K | +12.9% | -20.5% |
| Cash and Equivalents | June 30, 2022 | $5.08M | -53.4% | -23.0% |
| Stockholders Equity | September 30, 2025 | -$3.29M | -57.8% | -29.4% |
| R&D Expense | September 30, 2025 | $203.4K | -37.7% | -57.6% |
| Operating Income | September 30, 2025 | -$1.02M | +54.9% | +37.6% |
| Gross Profit | September 30, 2025 | $21.3K | +125.3% | +18.8% |
| Shares Outstanding | September 30, 2025 | 3.83M | +9.8% | +0.4% |
- Zivo Bioscience, Inc. reported Total Revenue of $157.2 thousand for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +468.6% in Total Revenue compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Revenue (ASC 606) of $157.2 thousand for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +468.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Net Income of -$13.38 million for fiscal year 2024.
- Zivo Bioscience, Inc. showed a decrease of -72.1% in Net Income compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Diluted EPS of $4.23 per share (loss) for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +8.0% in Diluted EPS compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Total Assets of $1.64 million for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +195.7% in Total Assets compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Cash and Equivalents of $1.80 million for fiscal year 2022.
- Zivo Bioscience, Inc. showed a decrease of -79.8% in Cash and Equivalents compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Stockholders Equity of -$514.9 thousand for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +76.7% in Stockholders Equity compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported R&D Expense of $3.13 million for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +127.7% in R&D Expense compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Operating Income of -$13.36 million for fiscal year 2024.
- Zivo Bioscience, Inc. showed a decrease of -84.0% in Operating Income compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Gross Profit of $49.0 thousand for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +321.6% in Gross Profit compared to the prior fiscal year.
- Zivo Bioscience, Inc. reported Shares Outstanding of 3.62 million shares for fiscal year 2024.
- Zivo Bioscience, Inc. showed an increase of +52.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: